Morotti, Andrea
Marini, Sandro
Lena, Umme K.
Crawford, Katherine
Schwab, Kristin
Kourkoulis, Christina
Ayres, Alison M.
Edip Gurol, M.
Viswanathan, Anand
Greenberg, Steven M.
Anderson, Christopher D.
Rosand, Jonathan
Goldstein, Joshua N.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (5R01NS073344, R01NS059727, K23AG02872605, K23 NS086873)
Article History
Received: 31 January 2017
Revised: 3 March 2017
Accepted: 4 March 2017
First Online: 10 March 2017
Compliance with ethical standards
:
: Joshua N. Goldstein reports research funding from Boehringer Ingelheim, Pfizer, and Portola; Advisory Board for Prolong Pharmaceuticals.
: This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: This study was supported by the following awards from the NINDS: 5R01NS073344, K23AG02872605, K23 NS086873, and R01NS059727. None of the funding entities had any involvement in study design; data collection, analysis, and interpretation; writing of the manuscript; or decision to submit the study for publication.